A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
| 适应症 | Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer |
|---|---|
| 分期 | 2期 |
| 申办方 | Compass Therapeutics |
| 状态 | 已完成 |
| 受试者人数 | 49 人 |
| 干预（药物） | CTX-009 |
| 开始日期 | 2022年12月8日 |
| 完成日期 | 2025年5月15日 |
| 结果公布日 | 2026年7月28日 |
摘要
This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer. A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.
Overall Response Rate
| CTX-009 10 mg/kg | 2 Participants |
|---|
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- CryoBalloon Ablation for Treatment of Duodenal Adenomas — Johns Hopkins University
- Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refract — Jennerex Biotherapeutics
- Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III — National Cancer Institute (NCI)
- Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps — National Cancer Institute (NCI)
- Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal — National Cancer Institute (NCI)
- Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating — National Cancer Institute (NCI)